Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 500 mg - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . caused by beta‑lactamase–pro

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 875 mg - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . caused by beta‑lactamase–pro

Καναδάς - Αγγλικά - Health Canada

angita pharma inc. - metoprolol tartrate - tablet - 25mg - metoprolol tartrate 25mg - beta-adrenergic blocking agents

Καναδάς - Αγγλικά - Health Canada

angita pharma inc. - metoprolol tartrate - tablet - 50mg - metoprolol tartrate 50mg - beta-adrenergic blocking agents

Καναδάς - Αγγλικά - Health Canada

angita pharma inc. - metoprolol tartrate - tablet - 100mg - metoprolol tartrate 100mg - beta-adrenergic blocking agents

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . caused by beta‑lactamase–pro

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

apotex corp. - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24) - antihistamine temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: - runny nose - sneezing - itchy, watery eyes - itching of the nose or throat

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - spironolactone - film-coated tablet - 100 milligram(s) - aldosterone antagonists; spironolactone

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

brillpharma (ireland) limited - trazodone hydrochloride - capsule, hard - 100 milligram(s) - other antidepressants; trazodone

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

brillpharma (ireland) limited - trazodone hydrochloride - film-coated tablet - 150 milligram(s) - other antidepressants; trazodone